AKT1 and thyroid cancer: In this study, we demonstrate that DSF/Cu can kill BRAFV600E-mutated thyroid cancer cells and improves their cellular response to BRAF kinase inhibitor by relieving feedback activation of MAPK/ERK and PI3K/AKT pathways in an ROS-dependent manner.